Klinické studie s perorálním roztokem citikolinu (Cognizin®) u pacientů s glaukomem:

• Rossetti L et al. The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter,randomized, placebo controlled cross over trial. Graefes Arch Clin Exp Ophthalmol. 2023;261:1659–1668.*

• Arrico L et al. Oral citicoline: influence of long-term therapy on perimetric glaucoma defects. Panminerva Med.. 2023 Mar;65(1):96-99.*

• Lanza M et al. Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A_Pilot Study With a_2-Year Follow-Up. Front Pharmacol. 2019 Sep 26; 10:1117.

• Ottobelli L. et al. Citicoline oral solution in glaucoma: is there a_role in slowing disease progression? Ophthalmologica. 2013;229(4):219-26.

* studie přímo s přípravkem NEUROTidine® v dávkování 10 ml/denně
(tj. 500 mg/denně perorálního rotzoku citikolin COgnizin(r).

Klinické studie s očním roztokem citikolinu:

• u pacientů s glaukomem
  
• oddělení (Perorálního roztoku a očních kapek)

Omk1

• Rossetti L et al. Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. J Glaucoma 2020;29:513–520.

• Carnevale C et al. Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution. PLoS ONE 2019:14(11): e0224982.

• Parisi V et al. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2015 Aug; 253(8):1327–40.

• Roberti G et al. A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian Journal of Ophthalmology 2014;62(5)549-553.

Omk1-LF

• Parisi V et al. Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. Adv Ther (2019) 36:987–996.

• u pacientů s počínající diabetickou retinopatií

Omk2

• Bandello F et al. Risultati della Survey Retinopatia Diabetica Incipiente REDI
  Studio osservazionale multicentrico in pazienti con Retinopatia Diabetica Incipiente, già in trattamento con Citicolina e Vitamina B12 in soluzione oftalmica NPT  Anno XXXIII 2023 n. 1/2023.

• Parisi V et al. Citicoline and Vitamin B(12) Eye Drops in Type 1 Diabetes: Results of a 36-Month Pilot Study Evaluating Macular Electrophysiological Changes. Adv Ther. 2021;38(7):3924-3936.

• Fogagnolo et al. Topical citicoline and vitamin B12 versus placebo in the treatment of diabetesrelated corneal nerve damage: a randomized double-blind controlled trial.  BMC Ophthalmology 2020;20:315.

• Parravano M et al. Citicoline and VitaminB12 Eye Drops in Type 1 Diabetes: Results of a 3-year Pilot Study Evaluating Morpho-Functional Retinal Changes. Adv Ther 2020;37:1646–1663.

Cognizin® je registrovaná značka společnosti KYOWA HAKKO BIO, Japonsko.
Přípravky Omk1, Omk1-LF a Omk2 obsahují citikolin od společnosti KYOWA HAKKO BIO, Japonsko.

Neurotidine® je potravina pro zvláštní lékařské účely.

Omk1, Omk1-LF a Omk2 jsou zdravotnické prostředky.